Email this LII item:
Postmarket Drug Safety Information for Patients and Providers
In 2005 the FDA proposed creating the Drug Watch Web Page, a new program that would communicate "the most up-to-date information possible on emerging [drug] safety issues to the public, even before FDA ... decides whether a regulatory action is appropriate." Includes guidance from the FDA, drug specific information for health professionals and consumers, and related information. From the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER).
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/default.htm
Asterisk
*
indicates required field.
Your Name
*
Your Email Address
*
Recipient Email Address(es)
*
(separate multiple addresses with commas)
Message
Enter the verification code as it is shown in the box below. This helps prevent automated submissions.
*
